ValuEngine downgraded shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) from a sell rating to a strong sell rating in a research report report published on Friday.

CHRS has been the subject of several other reports. Credit Suisse Group restated an outperform rating and issued a $17.00 price target (down from $24.00) on shares of Coherus BioSciences in a research note on Wednesday, September 27th. Zacks Investment Research upgraded Coherus BioSciences from a hold rating to a buy rating and set a $14.00 price target for the company in a research note on Tuesday, August 15th. Cowen and Company restated an outperform rating and issued a $45.00 price target on shares of Coherus BioSciences in a research note on Friday, September 8th. Citigroup Inc. restated a buy rating and issued a $23.00 price target on shares of Coherus BioSciences in a research note on Tuesday, November 7th. Finally, Maxim Group restated a buy rating and issued a $20.00 price target (down from $40.00) on shares of Coherus BioSciences in a research note on Friday, September 8th. Three analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $31.00.

Coherus BioSciences (NASDAQ:CHRS) traded down $0.55 during mid-day trading on Friday, hitting $10.05. The company had a trading volume of 576,100 shares, compared to its average volume of 527,353. The company has a current ratio of 5.46, a quick ratio of 4.27 and a debt-to-equity ratio of 1.84. Coherus BioSciences has a 1-year low of $10.00 and a 1-year high of $29.59.

Coherus BioSciences (NASDAQ:CHRS) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus BioSciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. equities analysts forecast that Coherus BioSciences will post -4.39 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Coherus BioSciences, Inc. (CHRS) Downgraded by ValuEngine to Strong Sell” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and republished in violation of US & international copyright & trademark laws. The legal version of this piece can be read at https://www.dailypolitical.com/2017/11/12/coherus-biosciences-inc-chrs-downgraded-by-valuengine-to-strong-sell.html.

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its position in shares of Coherus BioSciences by 32.7% during the 2nd quarter. SG Americas Securities LLC now owns 7,244 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 1,785 shares during the period. Legal & General Group Plc lifted its position in shares of Coherus BioSciences by 15.9% during the 1st quarter. Legal & General Group Plc now owns 8,295 shares of the biotechnology company’s stock valued at $173,000 after acquiring an additional 1,137 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Coherus BioSciences during the 2nd quarter valued at $185,000. Boston Advisors LLC bought a new stake in shares of Coherus BioSciences during the 2nd quarter valued at $244,000. Finally, Voya Investment Management LLC lifted its position in shares of Coherus BioSciences by 32.2% during the 2nd quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock valued at $253,000 after acquiring an additional 4,293 shares during the period. Hedge funds and other institutional investors own 78.12% of the company’s stock.

About Coherus BioSciences

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Analyst Recommendations for Coherus BioSciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.